Introduction
The permanent vaccination committee of Germany, in its epidemiological bulletin in July 2008, advises vaccinating premature infants according to the appropriate vaccinating age, regardless of their gestational week and weight at that time.
The maternal immunoglobulin concentration in very low birth weight premature infants is lower than that in term newborns. [1] [2] [3] The risk of falling ill with a preventable infection in which a vaccination exists is higher in the group of premature infants because of immature defense mechanisms. Second, the need for invasive treatment techniques holds a risk for infection. With less maternal immunoglobulin in circulation, an even more severe course of the illness could be present. [4] [5] [6] Among pediatricians, uncertainty exists as to whether the present recommendation is good because of possible severe adverse effects among very low birth weight babies. However, concern exists with regard to a sufficient antibody response in premature infants.
The study was undertaken to analyze adverse events associated with the immunization of very low birth weight children.
We hypothesized that adequate vaccination in very low birth weight children was associated with an increased risk for apnea and bradycardia with lower gestational age and that cerebral hemorrhage or periventricular leukomalacia did not aggravate side effects.
Methods
We included all premature infants with a birth weight below 1500 g who received their first vaccination during their primary hospitalization in the Children's Hospital Bult Hannover, Germany, between January 1998 and December 2006. Every infant was identified for vaccination after obtaining parental informed consent, when the infant had no septic condition and was not under corticoid treatment. Artificial ventilation or nasal continuous positive airway pressure was not a contraindication. Some of the infants were still under routine caffeine treatment because of apnea of prematurity. All children were on a cardiorespiratory monitor. The infants were monitored for respiration, heart rate and oxygen saturation.
In a prospective observational protocol, basic data such as birth weight, gestational week at birth, degree of cerebral hemorrhage, presence of periventricular leukomalacia, postconceptional age at the time of vaccination and weight, as well as the vaccine given, were recorded.
For up to 48 h, adverse events were documented by the nurse on duty as they would have been written down in the charts without vaccination. Adverse events included cardiorespiratory incidences (apnea, bradycardia and oxygen desaturations). Apnea was defined as cessation of respiration for X20 s, bradycardia as a decrease in heart rate to p90 beats per minute X 20 s, requiring intervention and a desaturation in oxygen saturation to p85%. In infants already suffering from single apnea/bradycardia events before immunization, only an increase in frequency was used as an adverse event, and the necessity of starting mechanical ventilation or continuing positive airway pressure was also documented. Other side effects observed were local reactions defined as redness at the injection side, swelling >2 mm and fever >38. 
Statistics
Continuous variables are expressed as the mean or median and comparative univariable analyses were made with the t-test, Mann-Whitney U test or Wilcoxon signed rank test. Binomial or ordinal data are expressed as percentages and comparative univariable analyses were made with the w 2 -test, two-sided Fisher's exact test or binomial logistic regression. A probability value of P<0.05 indicated a significant difference between groups.
Results of these analyses are expressed as odds ratios (OR) with 95% confidence intervals (CI) for variables with a value of P<0.05.
Statistic evaluations were performed with the intercooled Stata 8.2 Windows (Stata Corp LP, College Station, TX, USA).
Results
In all, 473 premature infants, who got their first routine vaccination, were included in this study. Fifty-eight (12%) of them still received caffeine.
The birth weight had a median of 910 (375 to 1495) g. The gestational week at birth had a median of 27.6 (22.6 to 34.3) weeks. The distribution of the patients to the three vaccine groups is shown in Table 1 .
With a median of 37.4 (31.5 to 48.3) gestational weeks, the vaccine was applied.
The mean age at the time of the vaccination was the highest in 1998 with 11.7±3.1 weeks and dropped significantly over the years to 8.6 ± 2.1 weeks in 2006. The frequency of adverse events in the whole group is shown in Table 2 . Between the vaccine groups there were no significant differences for local reactions or fever. Only one sterile abscess was observed. Apnea and bradycardia appeared significantly more often in group C than in the other two groups (Table 3) .
Infants showing apnea were born on an average 1.4 weeks earlier than those without apnea (26.3 ± 1.8 versus 27.7 ± 2.1 weeks). The chance of suffering from apnea decreased with increasing gestational week at birth. This corresponded with the finding that premature infants with a birth weight under 500 g and between 500 and 999 g had apneas significantly more often than did children with a birth weight of 1000 g or more. We did not find this correlation for bradycardia. Those premature infants who suffered from apnea did not show a significant difference at the time of vaccination in comparison with those without this adverse event (9.9 ± 1.7 weeks and 10 ± 2.1 weeks, respectively).
When comparing groups B and C and correcting for the age, there was a trend toward more apneas in group C but it did not reach significance (P ¼ 0.071).
When looking at the subgroup of infants who had a central nervous complication such as cerebral hemorrhage or periventricular leukomalacia, we found no significant correlation for apnea or bradycardia, but fever significantly more often in infants with cerebral hemorrhage grade 3-4 or with periventricular leukomalacia.
The chance for fever had an OR of 8.7 (2.1:35.9) in infants with cerebral hemorrhage grade 3-4 and OR of 8.2 (1.6:42.6) for those with a periventricular leukomalacia.
Forty-seven (9.9%) infants received a second vaccination during the first hospital stay. Twenty-six of the 47 infants had adverse events with the first vaccination for apnea or/and bradycardia. After the second vaccination, apnea and bradycardia occurred in only two premature infants. Neither of the two had these adverse events after the first vaccination. There was no association between late death and infants who suffered from apnea after the first vaccination.
No infant was advised readmission by the community pediatrician for apnea or for an acute life-threatening event after a second or third vaccination was carried out.
Discussion
Our study, with 473 infants, is one of the largest prospective immunization studies in premature babies with a birth weight under 1500 g. Over the years, a more timely vaccination, as recommended, was implemented in our cohort. This shows a clear learning effect on physicians that treat these infants. Tillmann et al. 7 reported in a group of premature babies in north-western Switzerland a significant delay when compared with full-term controls. This delay was mostly caused by insufficient information to parents about the importance of adequate timing of the vaccination, and the authors speculate that practitioners still believed that pre-term babies should be vaccinated according to their corrected age. This is in concordance with reports from Langkamp et al. 8, 9 in which parents and primary care physicians had incorrect knowledge of the right timing of vaccinating premature infants and consequently immunizations were delayed. 10 Another concern with the first immunization at 2 months, regardless of their corrected age, is an inadequate antibody response after the vaccination. Different groups [11] [12] [13] [14] analyzed the antibody response in premature babies and found over a longitudinal time lower antibody titres, but in most of them the antibody levels were in the protective range. Local reactions were rare, and training on the correct immunization technique is considered indispensable. Fever, too, was a rare event in the whole group. The more severe adverse events, such as apnea and bradycardia, occurred in 10.8% of the cases. The incidence increased significantly when the hexavalente immunization was combined with the pneumococcal conjugate vaccine. An explanation could be the higher amount of antigens. In contrast, the vaccination in group C was more timely than in the other groups. When correcting for age at the time of vaccination, there was only a trend to more apneas in group C, which can be interpreted to mean that the exposure to more antigens in group C was not the cause of more apneas. One needs to keep in mind that group B had only 51 patients compared with 260 patients in group C, which could also be an influencing factor.
When looking at the whole group that had apneas as an adverse effect, the timing of vaccinating for those who did not have this adverse event was not significantly different.
Carbone et al. 15 reported no difference in the frequencies of apneas and bradycardias in a group of 191 premature infants who were randomized to the DTaP group or had no vaccination. It was noticeable that in their cohort 53.4% in the DTaP group and 62.5% in the control group had prolonged apneas and/or prolonged bradycardias already during the pre-treatment phase. Thus, in this infant population, the risk for apneas or bradycardias was already given without immunization of the children. Infants of our cohort were treated routinely with nasal continuous positive airway pressure (CPAP) machine and/or caffeine to reduce apnea and bradycardia events.
Pourcyrous et al. 16 showed that cardiorespiratory adverse events were four times higher following the simultaneous administration of multiple vaccines than in a single vaccine application. In our whole group, we always used multiple vaccine combinations, but group C with a higher antigen exposure than the other combinations and showed a significantly higher incidence of apnea and bradycardia. Pfister et al. 17 reported an increase of up to 47% of cardiorespiratory events, which required monitoring and intervention but without severe impact on the infants' clinical course. In contrast, in our cohort the events were clearly less frequent with 10.8% overall and 15% in group C.
For decades, there has been concern for immunizing children with cerebral morbidity. For this reason, infants with neurological alterations such as cerebral hemorrhage and/or periventricular leukomalacia were evaluated separately. More often, they had fever without further complications. As the number of infants was small, no further calculation could be done. A clear rationale for this finding does not exist. Perhaps, it is only a bias of small numbers. The approach of Pourcyrous et al. 16 of giving acetaminophen to infants every 6 h within the first 48 h of immunization could prevent this adverse effect.
The limitations of the study were that the observational reports for apneas and bradycardias were not recorded online. The three vaccine groups did not have the same number of infants and gestational age as the time of vaccination decreased over the years. When combining groups A and B, they had the same vaccine combination and can be appreciated as a whole.
Conclusion
It is safe to vaccinate children according to the recommendations. Cardiorespiratory adverse events can appear, especially in the group of extremely low birth weight children, in concordance with lower postmenstrual weeks at vaccination. Premature infants with neurological alterations have no increased risk for cardiorespiratory adverse events.
